Clinical Trials on Gram-Positive Bacterial Infections

Total 8126 results

Henry M. Jackson Foundation for the Advancement...
Infectious Diseases Clinical Research Program

Completed

Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits (LTBI)

Latent Tuberculosis Infection

United States
National Taiwan University Hospital

Unknown

Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)

Latent Tuberculosis Infection

Taiwan
Centre Hospitalier Universitaire Vaudois
University of Witwatersrand, South Africa; Ecole Polytechnique Fédérale de... and other collaborators

Recruiting

Triage UltraSound in Tb Endemic Regions (TrUST)

Pneumonia | Tuberculosis | Lower Resp Tract Infection

Benin, Mali, South Africa
Singapore General Hospital

Unknown

A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections

Mycobacterium Infections, Nontuberculous

Singapore
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)

Pneumococcal Infections

Japan
Sinovac Biotech Co., Ltd

Completed

Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine

Pneumococcal Infections

China
Sinovac Biotech Co., Ltd

Completed

Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine

Pneumococcal Infections

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Pneumococcal Infections

United States, Australia, Canada, Finland, Germany, Israel, Malaysia, Peru, Taiwan, Thailand
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Pneumococcal Infections

Japan
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine

Pneumococcal Infections

China
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) (PNEU-AGE)

Pneumococcal Infections

Taiwan, United States, Canada, Japan, Spain
Arto Palmu
GlaxoSmithKline

Completed

Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage (FinIPcarr)

Pneumococcal Infections

Finland
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP606 in Healthy Toddlers

Pneumococcal Infections

Korea, Republic of
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Pneumococcal Infections

United States
GlaxoSmithKline

Completed

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children

Infections, Streptococcal

Japan
GlaxoSmithKline

Completed

Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib

Infections, Streptococcal

Netherlands
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Pneumococcal Infections
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
GlaxoSmithKline

Completed

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali

Infections, Streptococcal

Mali
GlaxoSmithKline

Completed

Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine

Infections, Streptococcal

Korea, Republic of
Pfizer

Completed

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

Pneumococcal Infections

United States
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

Infections, Streptococcal

Slovakia, Sweden, Denmark, Norway
GlaxoSmithKline

Completed

Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A

Infections, Streptococcal

Slovakia, Sweden
Agence de Médecine Préventive, France

Completed

Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso (PCV13-Bobo)

Pneumococcal Infections

Burkina Faso
GlaxoSmithKline

Completed

A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study

Infections, Streptococcal

Finland, France, Poland
GlaxoSmithKline

Terminated

Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines

Infections, Streptococcal

Philippines
Pfizer

Completed

13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

Pneumococcal Infections

Mexico
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Investigating Administration of Prevenar for Post-Marketing Surveillance

Pneumococcal Infections

Korea, Republic of
Centers for Disease Control and Prevention
Southcentral Foundation; Alaska Native Tribal Health Consortium

Completed

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders

Pneumococcal Infections

United States
VA Office of Research and Development
University of Wisconsin, Madison

Active, not recruiting

Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA (GLORI)

Clostridium Difficile

United States
The University of Texas Health Science Center,...

Withdrawn

Randomized Clinical Trial of Standard FMT Treatments (FMT)

Clostridium Difficile
Valneva Austria GmbH

Completed

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Clostridium Difficile

Germany, United States
Virginia Commonwealth University
Astellas Pharma Inc

Completed

The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

Staphylococcus Aureus

United States
University Hospital, Limoges

Completed

Community-acquired Methicillin-Resistant Staphylococcus Aureus Carriage Among Athletes (PSARM-S)

Staphylococcus Aureus
Hamilton Health Sciences Corporation
St. Joseph's Healthcare Hamilton; McMaster University

Completed

Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile

Clostridium Difficile

Canada
Michael E. DeBakey VA Medical Center
Baylor College of Medicine

Completed

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

Staphylococcus Aureus

United States
Nabi Biopharmaceuticals

Completed

StaphVAX Immunogenicity in Orthopedic Implant Patients

Staphylococcal Infections | Joint Prosthesis

United States
University of Sussex
Danone Institute International

Completed

Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection (NU278)

Diarrhoea | Clostridium Difficile

United Kingdom
NovaDigm Therapeutics, Inc.
United States Department of Defense

Completed

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Candidiasis | Staphylococcal Infections | Yeast Infections

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Determining Risk in Latent Tuberculosis

Latent Tuberculosis

Korea, Republic of
Public Health England

Completed

Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines (sched1)

Pneumococcal Infections | Meningococcal Infections

United Kingdom
Baylor College of Medicine
Allergan

Completed

Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

Osteomyelitis | Bone Infection | Hematogenously Acquired Staphylococcus Aureus Osteomyelitis

United States
Sheba Medical Center
The Israel Science Foundation

Recruiting

Mother to Newborn Transmission of Staphylococcus Aureus and Dynamics of S.Aureus Carriage During the First Years Life

Staphylococcus Aureus

Israel
University of Calgary
Canadian Institutes of Health Research (CIHR); Alberta Health services

Completed

C Difficile Near-patient Diagnostics

Clostridium Difficile

Canada
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company

Completed

Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients (ANTISTAPH)

Staphylococcus Aureus

France
Rothman Institute Orthopaedics

Unknown

Probiotics Pilot Project

Staphylococcus Aureus

United States
Mayo Clinic

Completed

Fresh Versus Frozen Stool for Fecal Transplant in Children

Clostridium Difficile

United States
Pfizer

Completed

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Clostridium Difficile

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Network on Antimicrobial Resistance in Staphylococcus Aureus

Staphylococcus Aureus

United States
Jared Brooks
Northwestern Medicine

Completed

Chlorhexidine Bathing Effect on Clostridium Difficile Rates

Clostridium Difficile

United States

Clinical Trials on Gram-Positive Bacterial Infections

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations